Savara Inc Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net
Savara Inc (SVRA) reported Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net of $116.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet · last filed 2021-11-12
- Savara Inc derivative instruments not designated as hedging instruments, gain (loss), net for the quarter ending 2020-09-30 was $60.00K.
| Period end | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 3 month | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 6 month | Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net 9 month |
|---|---|---|---|
| 2020-09-30 | $60.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $116.00K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $56.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |